NASDAQHealth CareBiotechnologySnapshot 2026-07-09
Reading RNA? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →Warn: Management is running behind on a stated commitment.
Atrium Therapeutics is advancing early-stage precision cardiology programs through partnerships with Bristol-Myers Squibb and Eli Lilly. The company reported an earnings beat in May 2026 and aims to leverage these collaborations to grow. Revenue is expected around $666,670 next quarter, showing some commercial progress. Management is stable, supporting execution on these growth initiatives.
The company remains unprofitable with a negative free cash flow yield of -1.87%. Consensus expects EPS losses of -$3.59 for 2026 and -$5.85 for 2027. Revenue estimates are low at about $21.6 million for 2026, indicating slow commercial traction. Litigation filed in February 2026 adds risk to the turnaround story.
The market is currently correcting with no clear consensus revenue growth or fair value established. The share price reflects uncertainty about the company’s ability to turn profitable and grow revenue meaningfully. Our view differs by focusing on the potential from strategic partnerships and early-stage program progress.
Breaks if: No material progress or setbacks in precision cardiology programs by end of 2026
Leverage collaboration agreements with Bristol-Myers Squibb and Eli Lilly through the separation to progress early-stage precision cardiology programs.
Breaks if: EPS loss worsens beyond -$5.85 in FY27
Breaks if: Revenue falls below $2 million in FY27
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
